B. Riley Is Buying This Drugmaker After Its Sell-Off

GTHX shares are trying to break through a former area of resistance

by Josh Selway

Published on Feb 11, 2019 at 2:15 PM

Cancer treatment specialist G1 Therapeutics (NASDAQ:GTHX) has seen its stock price decline precipitously since its Sept. 11 peak of $69.57, bottoming at $15.21 on Dec. 21 following a bear gap sparked by disappointing trial data from the company's cancer drug, trilaciclib. Since then, the shares have been steadily climbing the charts, trading up 2.3% at $21.73 today, on pace for their highest close since that gap, thanks to another bullish analyst note.

Specifically, B. Riley began coverage on GTXH with a "buy" rating and $55 price target, representing a 153% runway from current levels. This upbeat attention only mirrors the broader sentiment seen across the Street, where six of seven analysts say to buy the security. What's more, the average 12-month price target is all the way up at $69.50.

On a more negative note, short interest has been increasing on the equity since early December. The 2.37 million shares held by short sellers equated to 8.8% of the float, or 6.7 days' worth of buying power, based on average daily trading volumes.

Looking closer at the charts, G1 Therapeutics stock is attempting to push past its 40-day moving average, set to close above the trendline again today. The shares' rally attempts back in November and December were neatly blocked by this moving average.

gthx stock price


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.
Spotify Stock Shaky as Amazon Eyes Podcasts
Amazon's interest in podcasts puts SPOT in focus
AZO Shifts Higher After Earnings
AutoZone's fiscal third-quarter results beat estimates
One New Company Looks Ready To Clean Up On China’s Lithium Mess
Click to continue to advertiser's site.